相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Genentech will invest approximately $750 million in a new device fill-finish manufacturing facility at its Hillsboro, Oregon campus, doubling the size of the existing site. - The expansion is expected to create 250 high-wage manufacturing jobs and approximately 200 construction jobs, with commercial operations beginning in 2031. - The flexible facility will support advanced drug delivery devices such as pre-filled syringes and autoinjectors, enabling more convenient treatment outside hospital settings. - The investment advances Genentech's end-to-end U.S. manufacturing capabilities and strengthens the domestic medicine supply chain across oncology, immunology, and neurology.
- Chugai Pharmaceutical and UCSF have entered into a multi-year Master Collaboration Agreement to advance drug discovery research in disease biology, novel drug targets, and new therapeutic approaches. - The partnership will combine UCSF's translational research capabilities with Chugai's proprietary antibody engineering, SnipeTide™ macrocyclic peptide, and small molecule platforms. - An initial research project is already underway with a UCSF principal investigator, signaling immediate momentum under the new framework. - The agreement was facilitated by Chugai Partnering U.S., based in South San Francisco, and UCSF Innovation Ventures, reflecting Chugai's global open innovation strategy.
- Astex Pharmaceuticals and Genentech have entered an exclusive worldwide research collaboration and license agreement to develop small molecule drug candidates for breast cancer. - The deal leverages Astex's fragment-based drug discovery platform to target a key cell-cycle-dependent regulator, with Genentech assuming responsibility for preclinical and clinical development as well as global commercialization. - Astex will receive a $25 million upfront payment and is eligible for milestone payments potentially exceeding $490 million, plus tiered royalties on net sales. - The drug discovery program originated from an earlier collaboration between Astex, Newcastle University, and Cancer Research Horizons, targeting an area of high unmet need in breast cancer therapy.
- A pilot study of the Participant Engagement Portal (PEP) found that 84% of cancer clinical trial participants reported a positive experience using the digital tool. - The portal achieved 96% ease-of-access ratings and 93% survey completion ease, with 93% of users agreeing to be contacted for future research. - PEP successfully gathered social determinants of health data, with 100% of respondents providing zip codes and 94% disclosing ancestry or ethnic origin. - Community clinics outperformed academic medical centers in patient enrollment, though researchers noted the need for greater demographic diversity in future iterations.
- Flatiron Health published the VALID Framework in the Journal of Clinical Oncology Clinical Cancer Informatics, representing the first comprehensive peer-reviewed approach to evaluating AI-extracted real-world oncology data quality. - The three-pillar framework establishes methodological benchmarks for data integrity by comparing LLM extraction against expert human abstraction, implementing automated verification checks, and conducting replication analyses. - The framework enables Flatiron to process longitudinal records across millions of patients and over 1.5 billion data points while maintaining clinical rigor for high-stakes cancer care decisions. - This validation approach addresses the industry tradeoff between AI speed and scale versus rigorous validation requirements for clinical data extraction from electronic health records.
- Chugai Pharmaceutical has exercised its option to license Araris Biotech's proprietary AraLinQ linker-payload platform for developing novel antibody-drug conjugates against one selected target. - The AraLinQ technology enables efficient conjugation of multiple anticancer payloads to a single antibody, aiming to deliver tumor-selective therapeutic effects with enhanced efficacy and safety. - The licensing agreement includes immediate upfront payment to Araris with potential total consideration of up to USD 780 million through milestone payments and royalties. - Chugai plans to combine the AraLinQ technology with its core antibody engineering capabilities to create innovative cancer therapeutics for unmet medical needs.
- SanegeneBio has entered into a global licensing agreement with Genentech, granting exclusive worldwide rights to one of its RNAi programs for $200 million upfront. - The deal includes potential milestone payments totaling up to $1.5 billion plus tiered royalties, representing one of the largest RNAi licensing agreements. - Genentech will lead all future clinical development and commercialization activities while SanegeneBio handles early development work. - The collaboration leverages SanegeneBio's proprietary LEAD™ tissue-selective RNAi delivery technology platform for breakthrough siRNA medicines.
- Genentech announced a landmark agreement with the U.S. government to provide medicines for serious diseases to Medicaid patients at prices comparable to other wealthy countries. - The biotechnology company will expand its direct-to-patient program for influenza medicines through TrumpRx.gov platform to increase patient access. - As part of the deal, Genentech receives a three-year tariff exemption and protection from future pricing mandates while committing to a $50 billion U.S. investment. - The agreement supports over 11,000 jobs including construction of new facilities and reinforces Genentech's manufacturing expansion in North Carolina.
- Caris Life Sciences has entered into a multi-year collaboration with Genentech to identify and validate novel oncology targets in solid tumor tissue using Caris' repository of nearly 500,000 tumor samples. - The agreement provides Caris with $25 million in upfront and near-term payments, plus potential milestone payments of up to $1.1 billion and tiered royalties on net sales. - The collaboration combines Caris' multimodal data and tissue-based discovery platform with Genentech's therapeutic development expertise to advance first-in-class cancer medicines. - Caris Discovery will utilize integrated bioinformatics and wet-lab workflows to validate prioritized targets and support next-generation therapy development.
- Ventus Therapeutics announced a multi-year collaboration with Genentech to discover novel small-molecule candidates using its proprietary ReSOLVE® platform, which combines AI, machine learning, and biophysics. - The agreement includes an upfront payment and potential milestones exceeding $460 million plus tiered royalties, with Ventus handling virtual screening and Genentech managing development and commercialization. - ReSOLVE® uniquely models dynamic water networks in protein pockets to accelerate drug discovery, offering a computational approach to tackle challenging therapeutic targets across multiple disease areas.
